Cumberland Pharmaceuticals Inc.
CPIX
$6.29
-$0.33-4.99%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 18.18M | 18.39M | 18.39M | 17.95M | 18.74M |
| Total Other Revenue | 4.13M | 4.13M | 4.13M | 1.33M | 1.33M |
| Total Revenue | 22.30M | 22.52M | 22.52M | 19.28M | 20.07M |
| Cost of Revenue | 3.23M | 3.23M | 3.23M | 2.97M | 3.30M |
| Gross Profit | 19.07M | 19.29M | 19.29M | 16.31M | 16.77M |
| SG&A Expenses | 22.12M | 22.23M | 22.11M | 19.41M | 19.48M |
| Depreciation & Amortization | 2.04M | 2.04M | 2.03M | 2.48M | 2.55M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.73M | 31.90M | 31.70M | 28.93M | 29.45M |
| Operating Income | -9.43M | -9.39M | -9.18M | -9.65M | -9.38M |
| Income Before Tax | -9.30M | -9.20M | -8.94M | -9.50M | -9.08M |
| Income Tax Expenses | 36.70K | 38.50K | 40.30K | -39.90K | -34.20K |
| Earnings from Continuing Operations | -9.34 | -9.23 | -8.98 | -9.46 | -9.04 |
| Earnings from Discontinued Operations | -1.60M | 1.83M | 6.12M | 6.12M | 6.12M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 20.80K | 17.20K | 28.70K | 9.50K | -5.90K |
| Net Income | -10.92M | -7.38M | -2.84M | -3.33M | -2.93M |
| EBIT | -9.43M | -9.39M | -9.18M | -9.65M | -9.38M |
| EBITDA | -6.04M | -5.00M | -5.03M | -5.05M | -4.70M |
| EPS Basic | -0.73 | -0.49 | -0.19 | -0.23 | -0.21 |
| Normalized Basic EPS | -0.39 | -0.38 | -0.37 | -0.40 | -0.40 |
| EPS Diluted | -0.73 | -0.49 | -0.19 | -0.24 | -0.22 |
| Normalized Diluted EPS | -0.39 | -0.38 | -0.37 | -0.40 | -0.40 |
| Average Basic Shares Outstanding | 59.86M | 59.84M | 59.82M | 58.83M | 57.93M |
| Average Diluted Shares Outstanding | 59.86M | 59.84M | 59.82M | 58.83M | 57.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |